公开(公告)号：EP2470528A1

公开(公告)日：2012-07-04

申请号：EP10745280.7

申请日：2010-08-26

Applicant: Novartis AG

Inventor： COSTALES, Abran Q. ,  HUANG, Shenlin ,  JIN, Jeff (Xianming) ,  LIU, Zuosheng ,  PECCHI, Sabina ,  POON, Daniel ,  TELLEW, John ,  ZHANG, Qiong

IPC: C07D403/04 ,  A61K31/506 ,  A61P35/00

CPC classification number: C07D403/04 ,  A61K31/506 ,  A61K45/06

Abstract: The present invention provides compounds of Formula (I) or (II) wherein R
1 , R
1b , R
2 , R
3 , R
4 , R
5 , R
6 and R
7 are defined herein. The compounds of Formula (I) or (II) and pharmaceutical compositions thereof are useful for the treatment of B-Raf-associated diseases.

Abstract translation: 本发明提供了式（I）或（II）的化合物，其中R 1，R 1b，R 2，R 3，R 4，R 5，R 6和R 7如本文所定义。 式（I）或（II）的化合物及其药物组合物可用于治疗B-Raf相关疾病。

公开(公告)号：EP3063143A1

公开(公告)日：2016-09-07

申请号：EP14800191.0

申请日：2014-10-29

Applicant: Novartis AG

Inventor： BAGDANOFF, Jeffrey T. ,  DING, Yu ,  HAN, Wooseok ,  HUANG, Zilin ,  JIANG, Qun ,  JIN, Jeff Xianming ,  KOU, Xiang ,  LEE, Patrick ,  LINDVALL, Mika ,  MIN, Zhongcheng ,  PAN, Yue ,  PECCHI, Sabina ,  PFISTER, Keith Bruce ,  POON, Daniel ,  RAUNIYAR, Vivek ,  WANG, Xiaojing Michael ,  ZHANG, Qiong ,  ZHOU, Jianguang ,  ZHU, Shejin

IPC: C07D405/14 ,  C07D413/14 ,  C07D213/73 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/06 ,  C07D405/04 ,  C07D409/04 ,  C07D241/20 ,  A61K31/4418 ,  A61P35/00

CPC classification number: A61K31/497 ,  A61K31/44 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/4965 ,  A61K31/506 ,  A61K31/5355 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/553 ,  A61K45/06 ,  A61K2121/00 ,  C07D213/73 ,  C07D241/20 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/06 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D413/14 ,  C07D498/04

Abstract: The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.

Abstract translation: 本发明提供式（I）的化合物或其盐; 和这些化合物的治疗用途。 本发明还提供包含这些化合物的药物组合物，以及包含这些化合物与治疗性助剂的组合物。

公开(公告)号：EP1984350B1

公开(公告)日：2010-08-18

申请号：EP07716906.8

申请日：2007-01-22

Applicant: Novartis AG

Inventor： BURGER, Matthew ,  NI, Zhi-jie ,  PECCHI, Sabina ,  ATALLAH, Gordana ,  BARTULIS, Sarah ,  FRAZIER, Kelly ,  SMITH, Aaron ,  VERHAGEN, Joelle ,  ZHANG, Yanchen ,  WAGMAN, Allan ,  NG, Simon ,  PFISTER, Keith ,  POON, Daniel ,  LOUIE, Alicia ,  PICK, Teresa ,  BARSANTI, Paul ,  IWANOWICZ, Edwin ,  FANTL, Wendy ,  HENDRICKSON, Thomas ,  KNAPP, Mark ,  MERITT, Hanne ,  VOLIVA, Charles ,  WIESMANN, Marion ,  XIN, Xiahua

IPC: C07D401/04 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D417/12 ,  A61K31/506 ,  A61P35/00

CPC classification number: C07D401/04 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D417/12

Abstract: Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, and prodrugs thereof ; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.

公开(公告)号：EP2470528B1

公开(公告)日：2014-10-01

申请号：EP10745280.7

申请日：2010-08-26

Applicant: Novartis AG

Inventor： COSTALES, Abran Q. ,  HUANG, Shenlin ,  JIN, Jeff (Xianming) ,  LIU, Zuosheng ,  PECCHI, Sabina ,  POON, Daniel ,  TELLEW, John ,  ZHANG, Qiong

IPC: C07D403/04 ,  A61K31/506 ,  A61P35/00

CPC classification number: C07D403/04 ,  A61K31/506 ,  A61K45/06

公开(公告)号：EP1575940B1

公开(公告)日：2011-10-05

申请号：EP03786980.7

申请日：2003-11-21

Applicant: Novartis AG

Inventor： NUSS, John, M. ,  PECCHI, Sabina ,  RENHOWE, Paul, A.

IPC: C07D401/12 ,  C07D407/14 ,  C07D403/12 ,  C07D407/12 ,  C07D239/48 ,  C07D417/12 ,  C07D403/04 ,  C07D403/14 ,  C07D401/14 ,  A61K31/506 ,  A61P35/00

CPC classification number: C07D239/42 ,  C07D239/47 ,  C07D239/48 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14

Abstract: Compounds having formula I are provided where the variables have the values described herein. (I). Pharmaceutical formulations include the compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and combinations with other agents. A method of treating a patient comprises administering a pharmaceutical formulation according to the invention to a patient in need thereof.

公开(公告)号：EP2118087A1

公开(公告)日：2009-11-18

申请号：EP08729174.6

申请日：2008-02-06

Applicant: Novartis AG

Inventor： PECCHI, Sabina ,  NI, Zhi-jie ,  BURGER, Matthew ,  WAGMAN, Allan ,  ATALLAH, Gordana ,  BARTULIS, Sarah ,  NG, Simon ,  PFISTER, Keith, B. ,  SMITH, Aaron ,  ZHANG, Yanchen ,  MERRITT, Hanne ,  VOLIVA, Charles

IPC: C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  A61K31/5377 ,  A61P35/00

CPC classification number: C07D401/14 ,  C07D401/04 ,  C07D405/14 ,  C07D413/14

Abstract: Phosphatidylinositol (PI) 3-kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases, including proliferative diseases, inflammatory and obstructive airways diseases, allergic conditions, auutoimmune and cardiovascular diseases.

公开(公告)号：EP1989201A1

公开(公告)日：2008-11-12

申请号：EP07757005.9

申请日：2007-02-14

Applicant: NOVARTIS AG

Inventor： NI, Zhi-jie ,  PECCHI, Sabina ,  BURGER, Matthew ,  HAN, Wooseok ,  SMITH, Aaron ,  ATALLAH, Gordana ,  BARTULIS, Sarah ,  FRAZIER, Kelly ,  VERHAGEN, Joelle ,  ZHANG, Yanchen ,  IWANOWICZ, Ed ,  HENDRICKSON, Tom ,  KNAPP, Mark ,  MERRITT, Hanne ,  VOLIVA, Charles ,  WIESMANN, Marion ,  LEGRAND, Darren Mark ,  BRUCE, Ian ,  DALE, James ,  LAN, Jiong ,  LEVINE, Barry ,  COSTALES, Abran ,  LIU, Jie ,  PICK, Teresa ,  MENEZES, Daniel

IPC: C07D417/04 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04 ,  A61K31/437 ,  A61K31/5025 ,  A61K31/428 ,  A61P35/00

CPC classification number: C07D487/04 ,  C07D417/04 ,  C07D417/14 ,  C07D471/04

Abstract: Phosphatidylinositol (PI) 3 kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, phospholipid kinases, G-protein coupled receptors, and phosphatases.

公开(公告)号：EP2155202A2

公开(公告)日：2010-02-24

申请号：EP08759487.5

申请日：2008-05-09

Applicant: Novartis AG

Inventor： CAPRARO, Hans-Georg ,  CARAVATTI, Giorgio ,  FURET, Pascal ,  IMBACH, Patricia ,  LAN, Jiong ,  PECCHI, Sabina ,  SCHOEPFER, Joseph

IPC: A61K31/519 ,  A61K31/5025 ,  A61P29/00 ,  A61P37/00 ,  A61P35/00 ,  A61P11/00 ,  A61P11/06 ,  C07D487/04

CPC classification number: C07D487/04

Abstract: The present invention relates to compounds are of the formula I, processes for the preparation thereof, more generally these compounds for use in the treatment of the human or animal body, in the treatment of an inflammatory or obstructive airway disease, disorders commonly occurring in connection with transplantation, or a proliferative disease, which disease responds to an inhibition of kinases of the PI3-kinase-related protein kinase family.

公开(公告)号：EP1984350A1

公开(公告)日：2008-10-29

申请号：EP07716906.8

申请日：2007-01-22

Applicant: NOVARTIS AG

Inventor： BURGER, Matthew ,  NI, Zhi-jie ,  PECCHI, Sabina ,  ATALLAH, Gordana ,  BARTULIS, Sarah ,  FRAZIER, Kelly ,  SMITH, Aaron ,  VERHAGEN, Joelle ,  ZHANG, Yanchen ,  WAGMAN, Allan ,  NG, Simon ,  PFISTER, Keith ,  POON, Daniel ,  LOUIE, Alicia ,  PICK, Teresa ,  BARSANTI, Paul ,  IWANOWICZ, Edwin ,  FANTL, Wendy ,  HENDRICKSON, Thomas ,  KNAPP, Mark ,  MERITT, Hanne ,  VOLIVA, Charles ,  WIESMANN, Marion ,  XIN, Xiahua

IPC: C07D401/04 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D417/12 ,  A61K31/506 ,  A61P35/00

CPC classification number: C07D401/04 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D417/12

Abstract: Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, and prodrugs thereof ; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.

公开(公告)号：EP3063143B1

公开(公告)日：2018-05-16

申请号：EP14800191.0

申请日：2014-10-29

Applicant: Novartis AG

Inventor： BAGDANOFF, Jeffrey T. ,  DING, Yu ,  HAN, Wooseok ,  HUANG, Zilin ,  JIANG, Qun ,  JIN, Jeff Xianming ,  KOU, Xiang ,  LEE, Patrick ,  LINDVALL, Mika ,  MIN, Zhongcheng ,  PAN, Yue ,  PECCHI, Sabina ,  PFISTER, Keith Bruce ,  POON, Daniel ,  RAUNIYAR, Vivek ,  WANG, Xiaojing Michael ,  ZHANG, Qiong ,  ZHOU, Jianguang ,  ZHU, Shejin

IPC: C07D405/14 ,  C07D413/14 ,  C07D213/73 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/06 ,  C07D405/04 ,  C07D409/04 ,  C07D241/20 ,  A61K31/4418 ,  A61P35/00

CPC classification number: A61K31/497 ,  A61K31/44 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/4965 ,  A61K31/506 ,  A61K31/5355 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/553 ,  A61K45/06 ,  A61K2121/00 ,  C07D213/73 ,  C07D241/20 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/06 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D413/14 ,  C07D498/04

Abstract: The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.